AMS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMS exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position with a current ratio of 0.76. The company is experiencing a systemic decline, evidenced by a -14.80% YoY revenue contraction and a disastrous -200% YoY EPS growth. Despite a low Price-to-Book ratio of 0.37, the stock is in a technical freefall (0/100 trend) and consistently misses earnings estimates by wide margins. The combination of negative profitability and shrinking top-line growth suggests a value trap rather than a value opportunity.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AMS vs MRK: Head-to-Head Comparison
This page compares American Shared Hospital Services (AMS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.